Hepatitis B Virus Surface Antibody Screen, Qualitative/Quantitative, Serum
Use
Identifying previous exposure to hepatitis B virus. It helps determine the immune status of individuals with respect to HBV. A positive test indicates recovery from acute or chronic HBV infection or immunity from HBV vaccination. This assay is suitable for screening asymptomatic, nonpregnant individuals with or without risk factors for hepatitis B virus infection.
Special Instructions
Not provided.
Limitations
The assay is not FDA licensed for the screening of blood, plasma, and tissue donors. Positive results indicate either previous infection or successful vaccination but do not differentiate between these sources of immunity. False-positive results may occur if the individual received blood component therapy recently due to passive transfer of antibodies. Negative results should be interpreted with caution in immunosuppressed individuals. Biotin interference is possible; patients taking more than 300 mg of biotin daily should avoid such supplements before testing.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 5193-8 - HBV surface Ab SerPl IA-aCnc
- 5193-8 - HBV surface Ab SerPl IA-aCnc
- 10900-9 - HBV surface Ab Ser Ql IA
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.7 mL
Minimum Volume
0.6 mL
Container
Plastic vial
Collection Instructions
Centrifuge blood collection tube, aliquot serum into plastic vial within 2 hours of collection. Use serum gel collection container.
Patient Preparation
For 24 hours before specimen collection, patient should not take multivitamins or dietary supplements containing biotin.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus, Heat-inactivated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 6 days |
| Frozen | 90 days |